A method for preventing and treating one or more disease states including the steps of altering the diet of an individual and then administering a drug to the individual. Plasma vitamin C level is reduced from a first level to a second level that is lower than the first level, such that a pharmacological response of the body of the individual to a drug at the first level is different from the pharmacological response of the body of said individual to the drug at the second level.

The present invention comprises compositions that provide anti-glycation activity comprising a mineral extract composition or a mogroside/mineral extract composition or a mogroside composition. Such compositions are useful for methods of preventing, treating and inhibiting the effects of glycation in the body. The methods of the present invention comprise use of anti-glycation composition for the treatment and prevention of glycation related conditions including diabetes, atherosclerosis, arthritis, mental conditions and vision impairment.

Use of nano-sized lead borate compounds for treatment purposes due to their selective anticancer activity on p53 mutant breast cancer cell line, T47D is disclosed. The method of synthesizing nano-sized lead borates of the present invention comprises the steps of preparing a borate buffer solution by sodium hydroxide and boric acid, dissolving lead nitrate (and preferably PEG) in distilled water by stirring, mixing the borate buffer solution with the lead nitrate (and preferably PEG) solution, washing the resulting solution with distilled water and drying to remove the impurities.

Use of nano-sized lead borate compounds for treatment purposes due to their selective anticancer activity on p53 mutant breast cancer cell line, T47D is disclosed. The method of synthesizing nano-sized lead borates of the present invention comprises the steps of preparing a borate buffer solution by sodium hydroxide and boric acid, dissolving lead nitrate (and preferably PEG) in distilled water by stirring, mixing the borate buffer solution with the lead nitrate (and preferably PEG) solution, washing the resulting solution with distilled water and drying to remove the impurities.

Modified hydrophilic carbon clusters (HCCs), poly(ethylene glycol)-hydrophilic carbon clusters (PEG-HCCs) and similarly structured materials like graphene quantum dots (GQDs), PEGylated GQDs, small molecule antioxidants, and PEGylated small molecule antioxidants. These materials have been modified with an iron chelating moiety, deferoxamine, or a similar chelating moiety. By exploiting common binding sites, the carbon nanostructure facilitates intracellular transport including in mitochondria, reduces oxidative breakdown of the chelator moiety prior to treatment, and reduces both the cause and consequences of metal induced oxidative stress within the body thus providing a novel form of therapy for a range of oxidative and metal-related toxicities. Graphenic materials can be used for the treatment of acute and chronic mitochondrial electron transport chain dysfunction.

Modified hydrophilic carbon clusters (HCCs), poly(ethylene glycol)-hydrophilic carbon clusters (PEG-HCCs) and similarly structured materials like graphene quantum dots (GQDs), PEGylated GQDs, small molecule antioxidants, and PEGylated small molecule antioxidants. These materials have been modified with an iron chelating moiety, deferoxamine, or a similar chelating moiety. By exploiting common binding sites, the carbon nanostructure facilitates intracellular transport including in mitochondria, reduces oxidative breakdown of the chelator moiety prior to treatment, and reduces both the cause and consequences of metal induced oxidative stress within the body thus providing a novel form of therapy for a range of oxidative and metal-related toxicities. Graphenic materials can be used for the treatment of acute and chronic mitochondrial electron transport chain dysfunction.

Bacterial Vaginosis (BV) is caused by the bacterium Gardnerella Vaginalis. It affects 30% of women in the USA ages 14-49. It recurs frequently. Latoria's secret is a natural product, made of elements and compounds forming a solution, a vaginal suppository, and a soap. In Solution, water is 97% of the product. The element and other compounds are 2.5%. The blue color and ascorbic acid are less than 0.5% of the product. The water and other components are mixed to form Latoria's Secret Solution. They are mixed and placed in a vaginal squirt bottle. Latoria's Vaginal Suppository and Soap are made of the compound and a glycerinated gelatin base.

Bacterial Vaginosis (BV) is caused by the bacterium Gardnerella Vaginalis. It affects 30% of women in the USA ages 14-49. It recurs frequently. Latoria's secret is a natural product, made of elements and compounds forming a solution, a vaginal suppository, and a soap. In Solution, water is 97% of the product. The element and other compounds are 2.5%. The blue color and ascorbic acid are less than 0.5% of the product. The water and other components are mixed to form Latoria's Secret Solution. They are mixed and placed in a vaginal squirt bottle. Latoria's Vaginal Suppository and Soap are made of the compound and a glycerinated gelatin base.

The subject matter described herein is directed to stable L-cysteine compositions for injection, comprising: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount from about 10 mg/mL to about 100 mg/mL; Aluminum in an amount from about 1.0 parts per billion (ppb) to about 250 ppb; cystine in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; pyruvic acid in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; a pharmaceutically acceptable carrier, comprising water; headspace O.sub.2 that is less than 1.0%; dissolved oxygen present in the carrier in an amount from about 0.01 parts per million (ppm) to about 1 ppm, wherein the composition is enclosed in a single-use container having a volume of from 10 mL to 100 mL. Also described are compositions for a total parenteral nutrition regimen and methods for their use.

The subject matter described herein is directed to stable L-cysteine compositions for injection, comprising: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount from about 10 mg/mL to about 100 mg/mL; Aluminum in an amount from about 1.0 parts per billion (ppb) to about 250 ppb; cystine in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; pyruvic acid in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; a pharmaceutically acceptable carrier, comprising water; headspace O.sub.2 that is less than 1.0%; dissolved oxygen present in the carrier in an amount from about 0.01 parts per million (ppm) to about 1 ppm, wherein the composition is enclosed in a single-use container having a volume of from 10 mL to 100 mL. Also described are compositions for a total parenteral nutrition regimen and methods for their use.